Accelerating Cancer Drug Development Without Lowering the Bar

Every oncologist knows the feeling of watching a patient run out of time while a clinical trial crawls forward. The instinctive response is usually the same: we need to move faster. More trial sites. Shorter timelines. Fewer delays.

But here’s the uncomfortable truth: most oncology programs don’t fail because they moved too slowly. They fail because too many fundamental scientific questions remained unanswered.

In oncology, speed is rarely created by moving faster through development. More often, it is created by reducing uncertainty before development begins.

The Real Bottleneck Isn’t Time

When a drug program stalls or fails, the post-mortem often points to the same underlying issues: the wrong patients were enrolled, the biological target proved less important than expected, the optimal dose that was never fully understood, or resistance emerged sooner than anticipated.

These aren’t operational failures. They’re scientific ones.

Every oncology program begins with a series of critical questions. Does the target truly drive disease? Which patients are most likely to benefit? What dose achieves meaningful biological activity without unnecessary toxicity? How might resistance develop? How should the therapy fit into an increasingly complex treatment landscape?

Leave any of these questions unresolved and uncertainty begins to compound. One unanswered question several. By the time a pivotal trial begins, success depends not only on the therapy itself, but on a series of assumptions you made earlier.

Every unanswered scientific question eventually becomes a clinical question. Reducing uncertainty early doesn’t eliminate risk, but it makes development more predictable, and ultimately gives promising therapies a greater chance of reaching patients.[1]

Every Program Begins with Uncertainty

Uncertainty is an unavoidable part of innovation. Some programs explore entirely new biological mechanisms, whereas others build on well-characterized biology and still face uncertainty around patient selection, biomarkers, dosing strategies or therapeutic combinations.

The challenge is not whether uncertainty exists, but how much of it can be addressed before entering the clinic.

Novel mechanisms are particularly exciting because they have the potential to transform patient care. However, they also introduce additional questions. Is the biology truly disease-driving? Which patients should receive the therapy? Which biomarkers predict response? What resistance mechanisms are likely to emerge? How should the therapy be combined with existing standards of care?

These questions are not arguments against innovation. They are reminders that successful innovation depends on systematically reducing uncertainty throughout development rather than allowing it to accumulate.[2]

Reducing Uncertainty Before the Clinic

Modern oncology increasingly focuses on answering critical scientific questions as early as possible.

Advances in translational research, molecular profiling and biomarker development allow researchers to better understand disease biology before pivotal clinical trials begin. Early clinical studies can establish proof of mechanism, characterize pharmacology and help identify patients most likely to benefit.

This doesn’t eliminate uncertainty—drug development can never be completely predictable—but it changes its nature.

Programs that enter later-stage development with stronger biological rationale, clearer patient selection strategies and better characterized pharmacology are often better positioned to make confident development decisions.

Acceleration is therefore not simply about compressing timelines, but about entering development with fewer unanswered questions.

Dose Optimization as a Case Study

Dose selection illustrates how oncology thinking has evolved. For decades, oncology drug development largely followed a straightforward principle: identify the maximum tolerated dose and move forward.

While this approach made sense for many traditional cytotoxic therapies, it is not always appropriate for targeted therapies, where biological activity may plateau well below the maximum tolerated dose.

Recognizing this, the FDA’s Project Optimus initiative encourages sponsors to identify the biologically effective dose rather than simply the highest dose patients can tolerate. The objective is not only to improve tolerability, but to better understand the relationship between dose, biology, and clinical benefit before pivotal development begins.

Better dose optimization reduces uncertainty throughout development, It produces more predictable safety profiles, supports longer treatment duration where appropriate, and helps ensure that later-stage clinical trials evaluate therapies under conditions most likely to demonstrate meaningful patient benefit.[3][4]

Certainty as Infrastructure

Every major development decision is fundamentally a confidence decision. Are we sufficiently confident in the biology to continue investing? Do we understand which patients are most likely to respond? Have we selected the dose most likely to maximize benefit while minimizing unnecessary toxicity?

The more confidently these questions can be answered, the more efficient development becomes. Clinical trial design improves; resources are allocated more effectively; regulatory discussions become more focused; development decisions become more predictable.

Reducing uncertainty early is not conservative. It is one of the most patient-centric decisions a development team can make.

Every unsuccessful trial represents more than financial loss. It represents years during which patients continued to wait for better treatment options.[5]

What Speed Actually Looks Like

The oncology industry often talks about speed in terms of operational efficiency: faster enrollment, streamlined protocols, or shorter regulatory review timelines.

These improvements matter; but they are optimizations layered on top of something more fundamental.

Many of the fastest development programs move efficiently because critical scientific questions were answered long before the first patient was enrolled. They progress with greater confidence because target biology, patient selection, dose strategy and clinical rationale have already been strengthened.

This means the goal is not simply to move faster, it is to move forward with greater certainty.

What This Means Going Forward

Oncology is becoming more complex, not less. Tumour biology is increasingly understood at the molecular level, patient populations are becoming more precisely defined, and therapeutic strategies are becoming increasingly personalized.

In this environment, successful drug development will depend not only on generating new ideas, but on reducing uncertainty before those ideas reach the clinic. Programs built on stronger biological rationale, smarter patient selection and better-informed dose strategies are often better positioned to succeed — not because they are free of risk, but because they address it earlier.

At Helix BioPharma, we believe meaningful progress begins long before a pivotal clinical trial. It begins with a stronger scientific foundation, informed development decisions, and a commitment to understanding biology as deeply as possible.

Because in oncology, the fastest path to patients is often the one built on the strongest scientific foundations.

 

Ref:

1. Why early phase speed depends on oncology expertise. Worldwide Clinical Trials. April 20, 2026. Accessed June 16, 2026. https://www.worldwide.com/blog/2026/04/why-early%E2%80%91phase-speed-depends-on-oncology-expertise/

2. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2017;52:12-21. doi:10.1016/j.ctrv.2016.10.009

3. Fda.gov. Accessed June 16, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

4. Horning SJ, Haber DA, Selig WKD, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013;19(16):4297-4304. doi:10.1158/1078-0432.CCR-13-0523

5. Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal dosing for targeted therapies in oncology: Drug development cases leading by example. Clin Cancer Res. 2016;22(6):1318-1324. doi:10.1158/1078-0432.CCR-15-1295

Jacek Antas

Chief Executive Officer


Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

James B. Murphy

Chief Financial Officer


Mr. Murphy is a certified public accountant with over thirty years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC (“Danforth”), a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over fifteen private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over USD 0.5 billion in financing and successfully execute pivotal asset transactions. Mr. Murphy functions as a consultant to Helix pursuant to a consulting agreement between the Company and Danforth.

This will close in 0 seconds

Thomas Mehrling

Medical Adviser


Thomas Mehrling (PhD in Pharmacology and MD) has over 20 years’ experience in multinational Pharma companies developing novel oncology compounds from preclinical research through to registration. Prior to entering the industry, he spent 13 years as an MD at the University Hospital in Frankfurt, working on preclinical and translational projects. He served as Director of European Oncology at Mundipharma International (2003–2013), building the company’s first European oncology business from the ground up out of Cambridge, UK, and completing the clinical development, registration and launch of two major products in Europe, DepoCyte® and Levact® (Ribomustin® and Treanda®). In 2013, he led the establishment of the Mundipharma Group’s start-up, Mundipharma EDO, developing anti-cancer therapeutics for solid tumours out of Basel, Switzerland.

This will close in 0 seconds

Kim Gaspar

Director Quality Assurance


Kim is the Director of Quality Assurance at Helix BioPharma Corp. An experienced quality assurance professional with expertise in Canadian, US, and EU regulations, she has been involved in all aspects of Phase I/II biopharmaceutical product development over the years, including regulatory submissions, QC laboratory compliance, tech transfer and third-party oversight of CMC activities, clinical QA, and bioanalytical data analysis. Kim joined Helix in 2000, transitioning into QA in 2003. She holds a B.Sc in Biochemistry and a Ph.D in Veterinary Physiological Sciences, both from the University of Saskatchewan.

This will close in 0 seconds

Brenda Lee

Director Clinical Operations


Brenda is the Clinical Operations Director at Helix Biopharma Corp. A clinical research operations professional with 25 years of experience managing clinical trials, ranging from early Phase I to late Phase IIIb/IV studies, she brings experience in clinical study protocol writing and development, trial start-up and vendor management, and a proven track record in planning and managing clinical trials to quality standards, timelines and budget. Brenda joined Helix Biopharma Corp. in 2018, working to advance the clinical program of L-DOS47. She holds B.Sc and M.Sc. degrees from the University of Toronto, specializing in Nutritional Sciences and Human Biology.

This will close in 0 seconds

Jerzy Leszczynski

Director


Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Master of Science in Chemistry from the Warsaw Institute of Technology.

This will close in 0 seconds

Janusz Grabski

Director, Chair of Audit Committee


Janusz (John) Grabski is a lawyer specialized in corporate and real estate law with over twenty years of experience.

This will close in 0 seconds

Malgorzata Laube

Director


Malgorzata Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology and is based in Edmonton, Alberta, Canada.

This will close in 0 seconds

Jacek Antas

Chairman of the Board


Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

Jonathan Davis

Advisor, ADC Discovery


Jonathan Davis received his Ph.D. from University of California, San Francisco, where he studied protein structure and function using NMR. After a post-doc at Harvard Medical School exploring RNA selection and structure in the labs of Jack Szostak and Gerhard Wagner, he went to work at EMD Serono, where his work involved improving antibody-based therapeutics, inventing a platform technology for generating heterodimeric Fcs as a basis for multifunctional molecules, and developing a novel scaffold based on an artificially-designed protein from David Baker’s lab. In 2008 he took a job at Bristol-Myers Squibb in Waltham/Cambridge MA, working on antibody discovery and platform development in a wide range of therapeutic areas, with a particular focus on multispecific therapeutics. He moved to Madison, WI in 2019 to take on the role of VP of Innovation and Strategy at Invenra, a biotech focused on bispecific antibodies, and where he is currently head of the Scientific Advisory Board. In early 2024 he left the corporate world to found Creative Antibodies, a consulting firm that helps guide companies to successful antibody discovery and development projects, from mAbs to multispecifics, ADCs, and other formats. Outside of science, Jonathan is a conservatory trained cellist, plays numerous other instruments, and founded the UCSF Orchestra (now Symphony Parnassus) in San Francisco, where he was Music Director for six years.

This will close in 0 seconds

Davide Guggi

Advisor, CMC


Davide graduated as a pharmacist and received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. He has over 20 years of experience in the pharmaceutical industry, principally in the field of oncology. At the beginning of his career, Davide led oncology business units and commercial departments at Mundipharma and Gilead across Austria and Eastern Europe. Since over 10 years he has been working as a CMC expert, covering operational and regulatory CMC functions on behalf of over 20 different small- and medium-sized biotech companies across the world. He has served as CMC Director and CSO/CTO for several years, developing both small molecules and biologics (mABs, Fab, ADCs and Radio-immuno-conjugates) from early discovery to NDA/BLA in the US, EU and Canada, with a focus on First-in-Human and Phase I/II studies in oncology indications.

This will close in 0 seconds

This will close in 0 seconds

Tumor Defense Breaker™, L-DOS47


L‑DOS47 is a first‑in‑class, clinical-stage antibody‑enzyme conjugate designed to deliver a game-changing assist to anti-cancer immunity and today’s leading cancer immunotherapies for the treatment of prevalent, hard-to-treat solid tumors. The compound precisely targets CEACAM6, a cell-surface protein overexpressed in non‑small cell lung cancer (NSCLC) and other aggressive tumors, where it delivers an enzymatic payload that raises the extracellular pH of the acidic tumor microenvironment (TME). By neutralizing tumor acidity, L-DOS47 restores immune cell infiltration and activity, helps turn immunologically “cold” tumors “hot”, and enhances the therapeutic reach of immune checkpoint inhibitors. With patented composition-of-matter coverage through 2036 and demonstrated synergy with PD-1 inhibitor, pembrolizumab, L-DOS47 is poised to significantly increase the efficacy of immune checkpoint blockade and unlock broader and more durable responses in NSCLC and other aggressive solid tumors.

This will close in 0 seconds

LEUMUNA™


LEUMUNA™ is an oral immune checkpoint modulator designed to activate the donor immune system to recognize and fight relapsing leukemia in patients who have undergone allogeneic stem cell transplantation (allo-SCT). Although a life-saving procedure, up to 30% of patients who undergo allo-SCT see their cancer return, facing a median survival of just four months. LEUMUNA aims to offer these patients a new lease on life, by activating an immune cascade and inciting graft-versus-leukemia (GvL) effect, potentially offering long-term remission. Backed by strong preclinical data and a promising safety record from trials with its precursor compound, ulodesine, LEUMUNA offers a patient‑friendly, oral approach to a difficult-to-treat condition, with patent protection through 2041 and an Orphan Drug Designation granted by the US FDA.

This will close in 0 seconds

GEMCEDA™


GEMCEDA is a first-in-class oral prodrug of gemcitabine that opens up the possibility for convenient at-home administration, metronomic dosing and seamless integration into combination regimens with immune checkpoint inhibitors. To date, gemcitabine is only administered intravenously because oral forms have shown poor bioavailability of about 10%. GEMCEDA was developed as a prodrug to enable new uses of gemcitabine by combining it with cedazuridine, an enzyme inhibitor that helps boost its bioavailability to 90%. This remarkable innovation allows for greater flexibility in dosing schedules, fewer clinic visits, and a better quality of life, while achieving bioavailability on par with intravenous gemcitabine. Supported by a well‑established safety profile, scalable manufacturing, and patent coverage to 2043, GEMCEDA reimagines how chemotherapy can fit into patients’ lives.

This will close in 0 seconds